Abbott, Medtronic announce positive stent studies

10/22/2007 | Star Tribune (Minneapolis-St. Paul, Minn.)

Medtronic and Abbott Laboratories on Monday both highlighted the advantages of their respective drug-coated stents compared with Boston Scientific Corp.'s best-selling Taxus stent. One study showed that Medtronic's Endeavor was found to keep clogged arteries open for up to one year as well as Taxus and that its patients had fewer heart complications. Other data showed Abbott's Xience was able to lower the risk of heart attack, repeat surgery and death by 43% compared with Boston Scientific's stent.

View Full Article in:

Star Tribune (Minneapolis-St. Paul, Minn.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC